# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
FDA approves expanded indication making FILSPARI available to patients with IgA nephropathy (IgAN) at risk of progression; upda...
Benchmark analyst Robert Wasserman maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and raises the price target fro...
RBC Capital analyst Douglas Miehm reiterates Ligand Pharmaceuticals (NASDAQ:LGND) with a Outperform and maintains $130 price...
HC Wainwright & Co. analyst Joseph Pantginis reiterates Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and maintains $1...
RBC Capital analyst Douglas Miehm reiterates Ligand Pharmaceuticals (NASDAQ:LGND) with a Outperform and maintains $130 price...
Ligand Pharmaceuticals (NASDAQ:LGND) reported quarterly earnings of $1.40 per share which beat the analyst consensus estimate o...